CI values for FLT3 TKIs in combination with ATRA
| Cell line . | Sorafenib . | AC220 . | TTT-3002 . | |||
|---|---|---|---|---|---|---|
| CI (EC50) . | CI (EC90) . | CI (EC50) . | CI (EC90) . | CI (EC50) . | CI (EC90) . | |
| Molm14 | 0.32 | 0.46 | 0.48 | 0.68 | 0.53 | 0.47 |
| MV4-11 | 0.18 | 0.38 | 0.14 | 0.62 | 0.04 | 0.03 |
| Cell line . | Sorafenib . | AC220 . | TTT-3002 . | |||
|---|---|---|---|---|---|---|
| CI (EC50) . | CI (EC90) . | CI (EC50) . | CI (EC90) . | CI (EC50) . | CI (EC90) . | |
| Molm14 | 0.32 | 0.46 | 0.48 | 0.68 | 0.53 | 0.47 |
| MV4-11 | 0.18 | 0.38 | 0.14 | 0.62 | 0.04 | 0.03 |
CI values obtained by MTT assay at 48 hours, as in Figure 1, across a range of concentrations of ATRA (0-100 nM), sorafenib (0-20 nM), AC220 (0-10 nM), and TTT-3002 (0-5 nM) in equimolar ratios.
EC50, half maximal effective concentration; EC90, 90% effective concentration.